Dr. Amit Oza is Head of the Division of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret (PM) Cancer Centre. He is also co-Director of the Drug Development Program at PM Cancer Centre, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. He is the past co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and Executive Member of the international Gynecologic Cancer InterGroup. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM Cancer Centre. Under his direction the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally. Since 2011, he has obtained >$36.9M in peer-reviewed funding and has published >180 articles (all types) in journals, including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and the Journal of Clinical Oncology (IF=16.4).
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.
Cells. 2019 Feb 26;8(3):
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Gynecol Oncol. 2019 Feb 18;:
TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.
Int J Gynecol Cancer. 2019 Jan 18;:
Nat Rev Clin Oncol. 2018 Dec 19;:
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Gynecol Oncol. 2018 Nov 15;:
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov. 2018 Nov 13;:
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
Clin Cancer Res. 2018 Nov 09;:
Hematol Oncol Clin North Am. 2018 Dec;32(6):1041-1055
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
Genome Med. 2018 Oct 31;10(1):81
Hum Mutat. 2018 Nov;39(11):1593-1613
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Co-director, Robert and Maggie Bras and Family Drug Development Program
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology